Cases & Deals

Celgene successfully defends REVLIMID® compound patent against Kyle Bass' IPR petition

Clients Celgene Corporation

Jones Day represented Celgene Corporation in successfully defending an IPR petition filed by Coalition for Affordable Drugs VI LLC (CFAD) - a company formed by hedge fund manager Kyle Bass - against U.S. Patent No. 5,635,517, which is listed in the Orange Book for Celgene's REVLIMID® brand drug. Following Celgene's filing of its Patent Owner Preliminary Response, the PTAB denied CFAD's petition in its entirety, finding that CFAD had failed to establish a reasonable likelihood that it would prevail in showing the unpatentability of any claim of the '517 patent.

Coalition for Affordable Drugs VI LLC et al. v. Celgene Corporation, IPR2015-01169 (PTAB)

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.